Objective-Loss-of-function mutations in human hepatocyte nuclear factor 4␣ (HNF4␣) are associated with maturity-onset diabetes of the young and lipid disorders. However, the mechanisms underlying the lipid disorders are poorly understood. In this study, we determined the effect of acute loss or augmentation of hepatic HNF4␣ function on lipid homeostasis. Methods and Results-We generated an adenovirus expressing LacZ (Ad-shLacZ) or short hairpin RNA of Hnf4␣ (Ad-shHnf4␣). Tail vain injection of C57BL/6J mice with Ad-shHnf4␣ reduced hepatic Hnf4␣ expression and resulted in striking phenotypes, including the development of fatty liver and a Ͼ80% decrease in plasma levels of triglycerides, total cholesterol, and high-density lipoprotein cholesterol. These latter changes were associated with reduced hepatic lipogenesis and impaired very-low-density lipoprotein secretion. Deficiency in hepatic Hnf4␣ did not affect intestinal cholesterol absorption despite decreased expression of genes involved in bile acid synthesis. Consistent with the loss-of-function data, overexpression of Hnf4␣ induced numerous genes involved in lipid metabolism in isolated primary hepatocytes. Interestingly, many of these HNF4␣-regulated genes were not induced in wild-type mice that overexpressed hepatic Hnf4␣. Because of selective gene regulation, mice overexpressing hepatic Hnf4␣ had unchanged plasma triglyceride levels and decreased plasma cholesterol levels. Conclusion-Loss of hepatic HNF4␣ results in severe lipid disorder as a result of dysregulation of multiple genes involved in lipid metabolism. In contrast, augmentation of hepatic HNF4␣ activity lowers plasma cholesterol levels but has no effect on plasma triglyceride levels because of selective gene regulation. Our data indicate that hepatic HNF4␣ is essential for controlling the basal expression of numerous genes involved in lipid metabolism and is indispensable for maintaining normal lipid homeostasis. (Arterioscler Thromb Vasc Biol. 2011;31:328-336.)
N uclear receptors are ligand-activated transcription factors that regulate diverse physiological processes such as reproduction, development and metabolism. Hepatocyte nuclear factor 4␣ (HNF4␣, NR2A1) is a member of the nuclear receptor superfamily. It is highly expressed in the liver, with lower levels in the kidney, intestine, and pancreatic ␤ cells. 1, 2 Like other members of the nuclear receptor superfamily, HNF4␣ has a highly conserved DNA-binding domain and a variable ligand-binding domain. However, HNF4␣ is known to be constitutively active. Structural analysis of the ligand-binding domain of HNF4␣ indicates the C14 to C18 long-chain fatty acids are tightly bound to the hydrophobic pocket 3, 4 and cannot be dissociated from the receptor under nondenaturing conditions. 4 Recent data also show that linoleic acid selectively occupies the binding pocket of ligand-binding domain but does not affect the transcriptional activity of HNF4␣. 5 Together, these data indicate that under normal conditions, HNF4␣ activity is not affected by fatty acids, the endogenous ligands for HNF4␣.
Loss-of-function mutations in human HNF4␣ are associated with maturity-onset diabetes of the young (MODY1), 6 characterized by autosomal dominant inheritance, early-onset diabetes, and pancreatic ␤-cell dysfunction. 7 The diabetes phenotype appears to result from reduced insulin secretion in response to glucose stimulation. 8 In addition, patients with MODY1 also have reduced levels of plasma triglycerides and cholesterol. 9 -11 However, the mechanism underlying hypolipidemia remains poorly understood.
Homozygous mutations in whole body Hnf4␣ result in early embryonic lethality in mice, 12 consistent with the central role of HNF4␣ in development. Liver-specific Hnf4a Ϫ/Ϫ (L-Hnf4a Ϫ/Ϫ ) mice have increased plasma bile acid levels and reduced plasma levels of triglycerides and cholesterol. 13 The disorder in bile acid homeostasis is a result of reduced hepatic expression of genes involved in bile acid biosynthesis and bile acid uptake from the blood, 13, 14 whereas hypotriglyceridemia may result from reduced hepatic expression of microsomal transport protein (MTP) and apolipopro-tein B (ApoB), 13 2 proteins that play a critical role in very-low-density lipoprotein (VLDL) secretion. Hayhurst et al suggested that the increased expression of scavenger receptor class B type I (SR-BI), a high-density lipoprotein (HDL) receptor that selectively uptakes cholesteryl esters from plasma HDL, 15 is responsible for hypocholesterolemia observed in L-Hnf4␣ Ϫ/Ϫ mice. 13 It is unknown whether other genes or pathways are also involved in HNF4␣-regulated lipid homeostasis.
Both the liver and the intestine play an important role in maintaining cholesterol homeostasis. Plasma cholesterol levels may be affected by intestinal cholesterol absorption, hepatic de novo cholesterol biosynthesis, VLDL secretion, plasma cholesterol uptake by the liver, and subsequent hepatobiliary cholesterol secretion. HMG-coenzyme A (CoA) reductase is the rate-limiting enzyme in the cholesterol biosynthetic pathway. Once synthesized, cholesterol and long-chain fatty acids are esterified to form cholesteryl esters by acyl-CoA:cholesterol acyltransferase 2 (ACAT2; SOAT2) for storage or secretion in the form of VLDL from the liver or chylomicrons from the intestine. Plasma HDL levels may be affected by many factors. The data from human Tangier disease and genetically engineered mice have clearly demonstrated that ATP-binding cassette (ABC) transporter A1 (ABCA1) is the major determinant of plasma HDL levels. 16 -20 Hepatic ABCA1 has been shown to be responsible for Ϸ80% of plasma total HDL. 16 In addition, ApoA-I, the major component of HDL, is also required for maintaining plasma HDL cholesterol (HDL-C) levels. 21 Liver takes up plasma HDL-C or non-HDL-C via SR-BI, low-density lipoprotein receptor (LDLR) or LDLR-related protein (LRP). In the liver, cholesterol may be converted to bile acids by cholesterol 7␣-hydroxylase (CYP7A1) and sterol 12␣-hydroxylase (CYP8B1), 2 key enzymes that control bile acid biosynthesis. Bile acids are subsequently secreted to the bile via transporters, such as bile acid export protein (BSEP). Hepatic cholesterol may also be secreted directly to the bile via ABC transporters G5 (ABCG5) and G8 (ABCG8) 22, 23 or SR-BI. 24 In this report, we demonstrate that acute loss of hepatic Hnf4␣ causes hypotriglyceridemia and the development of fatty liver via reducing VLDL secretion. We also demonstrate that hepatic Hnf4␣ deficiency results in hypocholesterolemia, likely by reducing de novo cholesterol biosynthesis, VLDL secretion, and HDL biogenesis. In contrast, hepatic overexpression of HNF4␣ reduces the levels of hepatic triglycerides and plasma cholesterol but has no effect on plasma triglyceride levels. Together, these data demonstrate that hepatic HNF4␣ is essential for maintaining triglyceride and cholesterol homeostasis.
Materials and Methods
Mice C57BL/6J mice and db/db mice were purchased from the Jackson Laboratory (Bar Harbor, Maine) and fed a standard chow diet. All experiments were approved by the Institutional Animal Care and Use Committee at the Northeastern Ohio Universities College of Medicine. All mice were euthanized during the light cycle.
Adenovirus
Ad-Hnf4␣ was generated by cloning mouse Hnf4␣ cDNA to adenoviral vector pShuttle-IRES-hrGFP (Stratagene) as previously described. 25 To generate adenovirus expressing small hairpin RNA (shRNA) corresponding to ␤-galactosidase (Ad-shLacZ, control) or Hnf4␣ (Ad-shHnf4␣), oligonucleotides were designed using BLOCK-iT RNAi Designer (Invitrogen), annealed and ligated to pEnter/U6 vector (Invitrogen). Adenovirus was then generated following the instructions provided by Invitrogen. Three different shRNA oligonucleotides against murine Hnf4␣ were designed. The sequences that produced the most inhibitory effect on endogenous Hnf4␣ expression were 5Ј-CACCGGTGCCAACCTCAATTCATC-CCGAAGGATGAATTGAGGTTGGCACC-3Ј (top strand) and 5Ј-AAAAGGTGCCAACCTCAATTCATCCTTCGGGATGAATTG-AGGTTGGCACC-3Ј (bottom strand). Adenovirus was grown in 293A cells and purified using a BD Adeno-X Virus Purification Kit (BD Biosciences) or by cesium chloride density gradient centrifugation. To infect primary hepatocytes, adenovirus was added at a multiplicity of infection of 10, and cells were harvested after 48 hours. To overexpress genes in mice, 10 8 to 10 9 plaque formation units of adenovirus was transfused into each mouse via tail vain injection. To knock down hepatic genes in mice, 10 10 plaque formation units of Ad-shLacZ or Ad-shHnf4␣ was transfused to each mouse via tail vain injection. In general, 6 to 7 days postinfection, mice were fasted for 6 hours and then euthanized.
Primary Hepatocytes
Mouse primary hepatocytes were isolated and cultured as described. 26 Three days after isolation, hepatocytes were infected with adenovirus for 48 hours before RNA extraction.
Real-Time Polymerase Chain Reaction
RNA was isolated using TRIzol Reagent (Invitrogen), and mRNA levels were determined by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) using SYBR Green Supermix and a 7500 real-time PCR machine from Applied Biosystems (Foster City, Calif). The primer sequences for qRT-PCR are provided in Supplemental Table I , available online at http://atvb.ahajournals.org. Results were normalized to 36B4 mRNA.
Western Blot Assay
Whole liver lysates were prepared and Western blot assays were performed as described previously. 25 ␤-Actin antibody was from Novus Biologicals. HNF4␣ and MTP antibodies were from Santa Cruz Biotechnology. ApoB48/100 and ApoA-I antibodies were from Biodesign. Cyp7a1 antibody was a kind gift from David Russell at the University of Texas Southwestern Medical Center.
Chromatin Immunoprecipitation Assay
Adenovirus expressing green fluorescent protein (Ad-GFP) or Ad-HNF4␣ was used to infect primary hepatocytes for 48 hours, or C57BL/6 mice via intravenous injection. The protein lysates from the primary hepatocytes or the liver (6 days postinfection) were incubated with IgG or HNF4␣ antibody, and chromatin immunoprecipitation assays were performed as described previously (nϭ3 per treatment). 27
Glucose and Insulin Tolerance Test
Nine-week-old db/db mice were injected intravenously with Ad-shLacZ or Ad-shHnf4␣. On day 7, a glucose tolerance test was performed. Briefly, mice were fasted for 6 hours, followed by intraperitoneal injection of glucose (2 g/kg). Blood glucose levels were determined at indicated time points using an AlphaTrak glucometer (Abbott Laboratories). On day 9, an insulin tolerance test was performed. Mice were injected intraperitoneally with insulin (Humulin, 0.85 units/kg) after a 6-hour fast, and blood glucose levels were determined at the indicated time points.
Lipid Analysis
Approximately 100 mg of liver was homogenized in methanol, and lipids were extracted in chloroform/methanol (2:1 v/v) as described. 28 Hepatic triglyceride and cholesterol levels were then quantified using kits from Wako Chemicals (Richmond, Va). Plasma lipid levels were determined as described previously. 26 
VLDL Secretion
C57BL/6J mice were injected with either Ad-shLacZ or Ad-shHnf4␣ via tail vain injection. On day 6, these mice were fasted overnight, followed by intravenous injection of Tyloxapol (500 mg/kg). Blood was taken at the indicated time points, and plasma triglyceride levels were determined.
De Novo Lipogenesis
C57BL/6 mice were injected with either Ad-shLacZ or Ad-shHnf4␣. After 8 days and a 4-hour fast, mice were injected intraperitoneally with 2 H 2 O to get 3% enrichment. After 4 hours, livers were collected. Labeled and unlabeled palmitate and cholesterol were analyzed by mass spectrometry as previously described. 29 The fractional synthesis rate is expressed as follows: (Newly synthesized palmitate or cholesterol per gram liver/Total palmitate or cholesterol per gram liver)ϫ100%.
Intestinal Cholesterol Absorption
Intestinal cholesterol absorption was performed as described previously. 27, 30 Briefly, C57BL/6J mice were injected with Ad-shLacZ or Ad-shHnf4␣ via tail vain. After 6 days, mice were injected with 2.5 Ci of 3 H-cholesterol in Intralipid (Sigma) via tail vein injection, followed by immediate gavage with 1 Ci of 14 
Statistical Analysis
Statistical significance was analyzed using the unpaired Student t test, 1-way ANOVA, or Mann-Whitney test (GraphPad InStat3 software). All values are expressed as meanϮSEM. Differences were considered statistically significant at PϽ0.05.
Results

Acute Loss of Hepatic Hnf4␣ Results in Severe Lipid Disorder
To determine the effect of acute loss of hepatic HNF4␣ on lipid homeostasis, we generated 3 adenoviruses expressing shRNA corresponding to Hnf4␣ (Ad-shHnf4␣) and 1 to galactosidase Z (Ad-LacZ, control). One of 3 Hnf4␣ shRNAs was chosen for further studies, as it was particularly efficient in knocking down endogenous Hnf4␣ mRNA (Supplemental Figure IA ) and protein (Supplemental Figure IB) .
To test the physiological consequences of endogenous Hnf4␣ deficiency, we transfused Ad-shLacZ or Ad-shHnf4␣ to C57BL/6 mice via tail vain injection. Tail vain injection essentially limits adenovirus to the liver. As shown in Figure 1A , expression of Hnf4␣ shRNA significantly reduced hepatic Hnf4␣ mRNA levels by 67% but had no effect on the mRNA levels of Bsep and many other genes (data not shown), indicating that Hnf4␣ shRNA specifically and efficiently targets Hnf4␣ in vivo.
The livers of mice receiving Ad-shHnf4␣ were enlarged and white in color ( Figure 1B ). Analysis of hepatic lipid levels indicated that Hnf4␣-deficient mice had Ϸ4-fold increase in triglyceride levels ( Figure 1C ) and unchanged cholesterol levels in the liver ( Figure 1D ). These data demonstrate that hepatic Hnf4␣ deficiency leads to the development of fatty liver as a result of increased triglyceride accumulation.
In addition, Hnf4␣-deficient mice had strikingly low levels of plasma lipids; plasma triglyceride levels decreased by 84% ( Figure 1E ) and plasma total cholesterol and HDL-C levels decreased by Ϸ87% ( Figure 1F ). Together, the data shown in Figure 1 demonstrate that hepatic Hnf4␣ deficiency results in severe lipid disorder in both the liver and plasma.
Hepatic Hnf4␣ Deficiency Results in Dysregulation of Multiple Genes Involved in Lipid Metabolism
To understand the mechanism by which hepatic Hnf␣ deficiency results in lipid disorder, we analyzed hepatic gene expression by qRT-PCR. The data show that the mRNA levels of genes involved in VLDL secretion (Mtp, Apob), de novo cholesterol biosynthesis (Hmgcr, Hmgcs, Srebp-2), cholesterol catabolism (Cyp7a1, Cyp8b1), cholesterol esterification (Acat2, Lcat), and cholesterol uptake (Ldlr, SR-BI) were all significantly reduced in Hnf4␣-deficient mice (Figure 2A ). In addition, hepatic mRNA levels of genes encoding transporters (Abca1, Abcg5, Abcg8, Mdr2) ( Figure 2B ), apolipoproteins (Apoa1, Apoa2, Apoc2, Apoc3, and Apoe) ( Figure 2C ), or nuclear receptors (Ppar␣, Ppar␥) ( Figure 2D ) were also significantly reduced in Hnf4␣deficient mice. The finding that VLDL receptor (Vldr) ( Figure  2A ) and Abcg1 ( Figure 2B) were induced in Hnf4␣-deficient mice suggests that Hnf4␣ deficiency does not cause a global repression of genes involved in lipid metabolism. In addition, hepatic protein levels of Hnf4␣, Mtp (Figure 2E ) and ApoB48/ 100 ( Figure 2F ) were also significantly reduced in Hnf4␣deficient mice. Interestingly, hepatic Hnf4␣ deficiency did not significantly alter Cyp7a1 protein levels ( Figure 2E ), consistent with a previous report that Cyp7a1 protein levels are unchanged in L-Hnf4␣ Ϫ/Ϫ mice during the light cycle. 14 Together, these data indicate that HNF4␣ is important for normal expression of multiple genes that are involved in lipid metabolism.
Hnf4␣-Deficient Mice Have Impaired VLDL Secretion
The significant reduction in hepatic Mtp and Apob in Hnf4␣deficient mice (Figure 2 ) suggested that these mice likely had reduced VLDL secretion. We tested this hypothesis by injecting Tyloxapol, an inhibitor for lipoprotein lipase, to mice that had been infected with Ad-shLacZ or Ad-shHnf4␣ for 6 days. Hnf4␣-deficient mice had markedly reduced levels of plasma triglycerides ( Figure 3A) and ApoB48/100 secretion ( Figure 3B ) at 30, 60, and 90 minutes after injection of Tyloxapol, which corresponded to a 3.5-fold reduction in VLDL triglyceride production rate ( Figure 3C ). Thus, the data shown in Figure 3A to 3C demonstrate that hepatic HNF4␣ deficiency causes severely impaired VLDL secretion.
Hepatic HNF4␣ Deficiency Inhibits Lipogenesis and De Novo Cholesterol Biosynthesis
To determine whether hepatic HNF4␣ deficiency affects lipogenesis, we determined the mRNA levels of genes involved in lipogenesis. The data shown in Figure 3D show that sterol regulatory element-binding protein 1c (Srebp1c), acetyl-CoA carboxylase (Acc), and steroyl-CoA desaturase 1 (Scd-1) were unaffected, whereas the mRNA levels of fatty acid synthase (Fas), diacylglycerol acyltransferase (DGAT) 1 and DGAT2 were reduced in Hnf4␣-deficient mice. To determine the physiological consequences of such changes, we analyzed hepatic lipogenesis by injecting mice with 2 H 2 O; the data show that newly synthesized paltimate/fatty acid ( Figure 3E ) and cholesterol ( Figure 3F ) were significantly reduced in Hnf4␣-deficient mice. Together, these data demonstrate that hepatic HNF4␣ deficiency results in a significant reduction in lipogenesis and de novo cholesterol synthesis.
Hepatic Hnf4␣ Deficiency Does Not Affect Intestinal Cholesterol Absorption
Bile acids are involved in emulsification and absorption of dietary lipids. Loss of Cyp7a1 31, 32 or Cyp8b1 33 has been shown to reduce intestinal cholesterol absorption. Interestingly, hepatic Hnf4␣ deficiency reduced Cyp7a1 mRNA but not protein levels ( Figure 2 ). Previous data have shown that the ratio of cholic acid-derived metabolites to muricholic acid is similar between L-Hnf4␣ Ϫ/Ϫ mice and the control mice, 14 indicating that hepatic Hnf4␣ deficiency does not alter the hydrophobicity index of the bile acid pool and thus may not affect cholesterol absorption. Consistent with this latter finding, intestinal cholesterol absorption, determined by the plasma dual-isotope ratio method, 30 was unchanged between Hnf4␣-deficient mice and the control mice (Pϭ0.23) ( Figure  3G ). Thus, intestinal cholesterol absorption does not contribute to the reduced plasma cholesterol levels in hepatic Hnf4␣-deficient mice. 
Effect of Hepatic HNF4␣ Deficiency on Body Weight and Insulin Sensitivity
The striking phenotypes of fatty liver and hypolipidemia ( Figure 1 ) led us to investigate the role of hepatic Hnf4␣ deficiency in glucose homeostasis. In wild-type mice, hepatic Hnf4␣ deficiency had no effect on food intake, body weight, glucose tolerance, or insulin sensitivity (Supplemental Figure  II and data not shown). Interestingly, in 9-week-old db/db mice, infection with Ad-shHnf4␣ for 9 days caused a significant reduction in body weight ( Figure 3H ) but had no effect on food intake (data not shown). In addition, db/db mice receiving Ad-shHnf4␣ had increased glucose intolerance ( Figure 3I ) and increased insulin insensitivity ( Figure 3J ). These data indicate that hepatic HNF4␣ deficiency may be sufficient to cause insulin insensitivity.
Ex Vivo Expression of HNF4␣ Induces Many Genes Involved in Lipid Metabolism
Our loss-of-function studies have demonstrated that hepatic HNF4␣ is required for maintaining the expression of numerous genes involved in lipid metabolism (Figures 2 and 3) . To determine whether overexpression of HNF4␣ also alters these genes, we generated adenovirus expressing Hnf4␣ (Ad-Hnf4␣).
Ad-Hnf4␣ or Ad-GFP (control) was subsequently used to infect primary hepatocytes isolated from wild-type mice. Consistent with the loss-of-function data, overexpression of Hnf4␣ significantly induced the mRNA levels of Mtp, Apob (VLDL secretion), Cyp8b1 (bile acid synthesis), Lrp, Ldlr, SR-BI (cholesterol uptake), Acat2, Lcat (cholesterol esterification), Abca1, Abcg5, Abcg8 (transporters), Apoa1, Apoa2, and Apoc2 (apolipoproteins) (Table) . However, overexpression of Hnf4␣ had no significant effect on Srebp-2, Hmgcr, Srebp-1c, or Fas (Table) , suggesting that augmentation of hepatic HNF4␣ activity may not affect lipogenesis.
Hepatic Overexpression of HNF4␣ Lowers Plasma Cholesterol Levels But Not Triglyceride Levels
To determine the physiological consequences of overexpression of hepatic HNF4␣ in vivo, we transfused Ad-GFP or Ad-Hnf4␣ to C57BL/6 mice via tail vain injection. Overexpression of hepatic Hnf4␣ significantly increased hepatic Hnf4␣ protein levels ( Figure 4A ) and modestly reduced plasma total cholesterol levels but had no effect on plasma triglyceride levels ( Figure 4B ). Interestingly, overexpression of hepatic Hnf4␣ also reduced hepatic triglyceride levels but had no effect on hepatic total cholesterol levels ( Figure 4C) . Effect of hepatic HNF4␣ deficiency on VLDL secretion, lipogenesis, intestinal cholesterol absorption, and insulin sensitivity. A to D, C57BL/6 mice were injected with Ad-shLacZ or Ad-shHnf4␣ via tail vain injection (nϭ6 mice per group). After 6 days, mice were fasted overnight, followed by intravenous injection of Tyloxapol (500 mg/kg). Blood was taken at the indicated time points, and plasma triglyceride levels were determined (A). Plasma ApoB48/100 levels were determined by Western blot assays (B). The relative VLDL triglyceride (TG) production rate was determined by the slopes of linear increases of plasma TG (C). Hepatic mRNA levels were determined by qRT-PCR (D). E and F, C57BL/6 mice were infected with Ad-shLacZ or Ad-shHnf4␣ (nϭ5 to 6). After 8 days, mice were injected intraperitoneally with 2 H 2 O, and hepatic palmitate (E) and cholesterol synthesis (F) were determined. G, Intestinal cholesterol absorption was determined using plasma dual-isotope ratio method (nϭ5). H to J, Nine-week-old db/db mice were injected intravenously with Ad-shLacZ or Ad-shHnf4␣ (nϭ6 mice per group). Body weight (H) was determined, and the glucose tolerance test (I) and insulin tolerance test (J) were performed. *PϽ0.05, **PϽ0.01 versus Ad-shLacZ treatment.
In addition, overexpression of hepatic Hnf4␣ had no effect on intestinal cholesterol absorption (data not shown). Analysis of plasma by fast protein liquid chromatography indicated that overexpression of Hnf4␣ in the liver primarily lowered plasma HDL-C and had not much effect on VLDL or low-density lipoprotein cholesterol ( Figure 4D ). Overexpression of hepatic Hnf4␣ also tended to reduce VLDL triglycerides ( Figure 4E ). In addition, overexpression of hepatic Hnf4␣ had no effect on intestinal cholesterol absorption (data not shown). Together, the data shown in Figure 4 indicate that overexpression of hepatic HNF4␣ lowers plasma cholesterol levels, primarily by lowering HDL-C, and reduces hepatic triglyceride levels.
Overexpression of Hepatic HNF4␣ Selectively Regulates Gene Expression
The data in Figure 5A show that overexpression of hepatic Hnf4␣ increases the mRNA levels of Apob, Cyp8b1, SR-BI, and Apoc2 ( Figure 5A ) but did not affect the mRNA levels of Hmgcr, Hmgcs, Cyp7a1, Abca1, Abcg5, Abcg8, Apoa1, Acat2, Lcat, or Srebp-1c ( Figure 5A ). The levels of hepatic Mtp were highly variable; hepatic Mtp mRNA ( Figure 5A ; Pϭ0.06) and protein levels ( Figure 5B ) tended to increase following overexpression of HNF4␣ in the liver. Overexpression of Hnf4␣ in the liver had no effect on plasma ApoB48/ 100 levels ( Figure 5C ), consistent with unchanged plasma triglyceride levels (Figure 4 ). In addition, the induction of hepatic SR-BI following overexpression of Hnf4␣ in the liver ( Figure 5A ) is consistent with reduced plasma HDL-C levels (Figure 4 ).
The finding that HNF4␣ overexpression induces many genes in isolated primary hepatocytes (Table) but not in the liver (Figure 5A) is intriguing. Compared with the liver, primary hepatocytes had much lower levels of Hnf4␣ mRNA (Ͻ6%; data not shown) and protein ( Figure 5D ). We hypothesized that many genes were inducible in primary hepatocytes by exogenous HNF4␣ because endogenous HNF4␣ expression was low in these cells; we also hypothesized that many of these genes were not inducible in the liver by exogenous HNF4␣ because endogenous HNF4␣ expression was already high in vivo. We used Abcg5, which is a known HNF4␣ target gene 34 and is highly inducible by HNF4␣ in isolated primary hepatocytes (Table) but not in the liver (Figure 5A ), as an example to test our hypothesis.
HNF4␣ regulates Abcg5 expression through binding to a specific direct repeat (DR)-1 element in the Abcg5 promoter. 34 We infected primary hepatocytes with Ad-GFP (control) or Ad-HNF4␣, followed by chromatin immunoprecipitation assays; the data indicated that HNF4␣ protein bound to the Primary hepatocytes were infected with Ad-GFP or Ad-HNF4␣ for 48 hours. mRNA levels were quantified by qRT-PCR. Fold changes indicate the relative mRNA levels induced by HNF4␣ vs GFP (control).
Figure 4.
Overexpression of HNF4␣ in the liver lowers plasma cholesterol levels but has no effect on plasma triglyceride levels. C57BL/6 mice were injected intravenously with adenovirus expressing GFP (Ad-GFP) or HNF4␣ (Ad-HNF4␣) (nϭ5 mice per group). After 6 days, mice were fasted for 5 hours before euthanization. Hepatic protein levels were determined by Western blot assays (A). Triglyceride (TG) and total cholesterol (TC) levels in the plasma (B) and liver (C) were determined. Plasma cholesterol lipoprotein profile (D) and triglyceride lipoprotein profile (E) were determined by fast protein liquid chromatography analysis. *PϽ0.05 versus Ad-GFP treatment.
known DR-1 element only when HNF4␣ was overexpressed in isolated primary hepatocytes ( Figure 5E, left) . In contrast, HNF4␣ protein bound to the known DR-1 element in both the absence and the presence of exogenous HNF4␣ protein, and the expression of exogenous HNF4␣ protein did not further increase the recruitment of HNF4␣ protein to the DR-1 element in Abcg5 promoter ( Figure 5E, right) . Thus, the data shown in Figure 5D and 5E suggest that the difference in the abundance of endogenous HNF4␣ between the liver and primary hepatocytes is responsible for the differential regulation of certain genes by exogenous HNF4␣.
Discussion
In this study, we used loss-of-function and overexpression approaches to determine the role of hepatic HNF4␣ in lipid homeostasis. Acute loss of hepatic HNF4␣ resulted in striking phenotypes, including low blood triglyceride and cholesterol levels, fatty liver, and hepatomegaly (Figure 1) . These changes were associated with reduced lipogenesis, de novo cholesterol synthesis, and VLDL secretion. Consistent with changes, the expression of numerous genes that are involved in lipid metabolism was significantly altered. In addition, acute loss of hepatic HNF4␣ was also associated with increased glucose intolerance ( Figure 3 ). Interestingly, overexpression of HNF4␣ in the liver also moderately lowered plasma cholesterol levels but had no effect on plasma triglyceride levels ( Figure 4 ). Together, these data demonstrate that hepatic HNF4␣ is indispensable for maintaining normal triglyceride and cholesterol homeostasis.
The hypolipidemic effect of acute loss of hepatic Hnf4␣ reported in the current study is consistent with a previous study that used L-Hnf4a Ϫ/Ϫ mice. 13 In the latter report, however, the investigators attributed the hypocholesterolemia to increased hepatic SR-BI expression. 13 In the current study, we demonstrated that acute loss of hepatic Hnf4␣ reduces SR-BI expression (Figure 2A ). We noted the methodological difference between our studies and the studies by Hayhurst et al, 13 which includes knockdown methods (shRNA versus Cre-loxP), time (6 to 7 days versus 45 days), and the degree of Hnf4␣ deletion (67% versus Ͼ90%). Importantly, our loss-of-function data are supported by the finding that overexpression of HNF4␣ increases SR-BI expression in both isolated primary hepatocytes (Table) and the liver ( Figure  5A ). We also demonstrated that hepatic Hnf4␣ deficiency results in reduced expression of genes involved in de novo cholesterol biosynthesis (Hmgcs, Hmgcr), VLDL secretion (Mtp, Apob), and HDL biogenesis (Abca1, Apoa1) ( Figure 2) . We further demonstrated that such changes in gene expression have functional consequences; hepatic HNF4␣ deficiency reduces de novo cholesterol synthesis and VLDL secretion (Figure 3) . In addition, we demonstrated that hepatic HNF4␣ deficiency has no effect on intestinal cholesterol absorption ( Figure 3G ). Thus, our data show that the reduced plasma cholesterol levels in Hnf4␣-deficient mice may result from reduced de novo cholesterol synthesis and VLDL secretion.
Both the current study and a previous study 13 have demonstrated that loss of hepatic Hnf4␣ decreases hepatic Mtp and Apob expression. However, the functional significance of such changes has not previously been documented. In this study, we showed that hepatic VLDL secretion is severely impaired in Hnf4␣-deficient mice ( Figure 3A to 3C) . Consistent with reduced levels of Fas, Dgat1, and Dgat2 ( Figure  3D) , hepatic HNF4␣ deficiency also significantly reduced lipogenesis ( Figure 3E) . Consequently, the current data demonstrate that the development of fatty liver and hypotriglyc- Figure 5 . Overexpression of HNF4␣ in the liver selectively regulates gene expression. A to C, C57BL/6 mice were injected intravenously with Ad-GFP or Ad-HNF4␣ (nϭ5 mice per group). After 6 days, mice were fasted for 5 hours before euthanization. Hepatic mRNA levels were determined by qRT-PCR (A). Hepatic (B) and plasma (C) protein levels were determined by Western blot assays. D, Protein levels in isolated primary hepatocytes and the liver were determined. E, Chromatin immunoprecipitation assays were used to determine the enrichment of HNF4␣ protein in the promoter of the Abcg5 gene (nϭ3 per treatment). *PϽ0.05 versus Ad-GFP treatment. NS indicates not significant. eridemia following acute loss of hepatic HNF4␣ results from severely impaired VLDL secretion.
Loss of HNF4␣ in pancreatic ␤-cells is known to impair glucose-stimulated insulin secretion. 8 The role of loss of hepatic HNF4␣ in insulin sensitivity has not been investigated before. In this report, we show that acute loss of hepatic Hnf4␣ in diabetic db/db mice aggravates glucose intolerance and insulin insensitivity ( Figure 3I and 3J) . Such a phenotype may partially result from massive lipid accumulation in the liver and changes in the expression of genes involved in glucose metabolism. Detailed investigation into the role of hepatic HNF4␣ in glucose metabolism is one of our future directions. Nonetheless, our data suggest that hepatic HNF4␣ deficiency may also cause insulin insensitivity.
Compared with the emerging data from loss-of-function studies, little is known about the role of increased hepatic HNF4␣ activity in lipid metabolism. Here we show that overexpression of HNF4␣ in isolated primary hepatocytes induces many genes that are involved in lipid metabolism (Table) . Interestingly, only some of these genes are also induced in mice overexpressing hepatic Hnf4␣ ( Figure 5A ). The data shown in Figure 5E suggest that the difference in endogenous HNF4␣ protein levels between primary hepatocytes and the liver may account, at least in part, for the differential gene regulation by exogenous HNF4␣. Certain genes remain inducible in the liver by exogenous HNF4␣ (Figure 5A ), which may be accounted for by the existence of multiple DR-1 elements in these genes. For instance, both SR-BI 27 and Abcg5 34 are known HNF4␣ target genes and have 3 DR-1 elements and 1 DR-1 element, respectively; SR-BI, but not Abcg5, can be induced by exogenous HNF4␣ in the liver ( Figure 5A ). Consistent with the selective induction of certain genes in vivo ( Figure 5 ), hepatic overexpression of Hnf4␣ does not affect plasma triglyceride levels but modestly reduces plasma cholesterol levels (Figure 4 ). Because hepatic overexpression of SR-BI is known to reduce plasma cholesterol levels, 24 our data suggest that the reduced plasma cholesterol levels in Hnf4␣-overexpressing mice may result from increased hepatic SR-BI expression ( Figure 5 ). Interestingly, overexpression of HNF4␣ in the liver also reduces hepatic triglyceride levels, which may be accounted for in part by increased hepatic ApoB expression ( Figure 5A ).
In summary, we have used loss-of-function and overexpression approaches to demonstrate that hepatic HNF4␣ is required for maintaining basal expression of many genes involved in lipid metabolism and is indispensable for maintaining normal lipid homeostasis. Our data indicate that augmentation of hepatic HNF4␣ activity has only modest effects on lipid homeostasis.
